We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Microchip Biotechnologies Selected for Participation in the US Army Commercialization Pilot Program

News  
Published: January 7, 2008
 
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy
Read time: Less than a minute

Microchip Biotechnologies, Inc. (MBI) has been selected for participation in the inaugural US Army Commercialization Pilot Program. The Commercialization Pilot Program is a new program to identify SBIR firms that have Phase II projects with high transition potential to commercial products that meet high priority Army requirements.

MBI was identified as one of 25 firms selected out of 529 eligible firms and 416 applicants. MBI has been developing a biothreat detection system under Army SBIR funding.

"The acceptance of MBI by the Army to participate in the CPP is a further validation of our commitment to develop and commercialize microfluidic technologies for the protection of the combat troops and civilian populations," said Dr. Stevan Jovanovich, President and CEO of MBI.

Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter